HER-Vaxx is a proprietary HER-2+ cancer immunotherapy that targets the same well established cancer biomarker as Herceptin®

Imugene (ASX; IMU) is an immuno-oncology focused biopharmaceutical company developing HER-2+ gastric and breast cancer immunotherapies.

View interview (click here) and presentation (click here) by Imugene Director Dr Axel Hoos. View video that introduces HER-Vaxx and explains how it works (click here)


Our lead product is HER-Vaxx, a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the $US6.9 billion per annum drug Herceptin®.

Click here to view Imugene's current share price

Click here to view cancer vaccines article featuring Imugene and Mr Charles Walker


HER-Vaxx has successfully completed a Phase 1 study in breast cancer and the next stage of development will be a Phase 2 study in gastric cancer.  Gastric or stomach cancer is the second most common cause of cancer-related death in the world and the fourth most commonly diagnosed cancer, with over 1,000,000 new cases diagnosed each year.

HER-Vaxx has shown success in stimulating the production of lifesaving HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. Its further development is directed towards providing a natural, potentially more potent alternative to Roche’s popular injectable antibody, Herceptin®, which has become one of the world’s bestselling cancer drugs with annual sales in excess of $US6.9 billion (CHF6.08 billion, Roche Investor Update 30/1/14).

Imugene’s corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria.


© Imugene 2015. All rights reserved. ABN 99 009 179 551